

IL-27 Antibody (N-term) Blocking peptide
Synthetic peptide
Catalog # BP1707a**Specification**

IL-27 Antibody (N-term) Blocking peptide - Product InformationPrimary Accession [Q8TAD2](#)**IL-27 Antibody (N-term) Blocking peptide - Additional Information****Gene ID** 53342**Other Names**

Interleukin-17D, IL-17D, Interleukin-27, IL-27, IL17D, IL27

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP1707a](/product/products/AP1707a) was selected from the N-term region of human L27. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

IL-27 Antibody (N-term) Blocking peptide - Protein Information**Name** IL17D**Function**

Induces expression of IL6, CXCL8/IL8, and CSF2/GM-CSF from endothelial cells.

Cellular Location

Secreted.

Tissue Location

Expressed preferentially in adipose, skeletal muscle and CNS.

IL-27 Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

IL-27 Antibody (N-term) Blocking peptide - Images

IL-27 Antibody (N-term) Blocking peptide - Background

L27 is a cytokine that shares the sequence similarity with IL17. The treatment of endothelial cells with this cytokine has been shown to stimulate the production of other cytokines including IL6, IL8 and CSF2/ GM-CSF. The increased expression of IL8 induced by this cytokine was found to be NF-kappa B-dependent.

IL-27 Antibody (N-term) Blocking peptide - References

Clark, H.F., et al., Genome Res. 13(10):2265-2270 (2003). Starnes, T., et al., J. Immunol. 169(2):642-646 (2002).